Wayne State University/Detroit Medical Center - Internal Medicine.University of Chicago Medical Center - Hematology/Oncology.He oversees both autologous and allogeneic hematopoietic stem cell transplants as well as cellular immunotherapy treatments such as CAR T cell Therapy. Locke provides care for multiple myeloma, lymphoma, and leukemia patients. Locke received Medical Oncology, clinical research, and laboratory research training at the University of Chicago. He stayed at Wayne State and the Detroit Medical Center for Internal Medicine residency training and then served as Chief Medical Resident at Detroit Receiving. in Physiology from Michigan State University, and with an M.D. Locke is translating findings from his laboratory into new cellular immunotherapies such as the Moffitt created whole protein survivin tumor vaccine for multiple myeloma. for several pivotal trials of anti-CD19 CARs for lymphoma. Locke is a clinical research leader in the field of Chimeric Antigen Receptor (CAR) T cell therapy, acting as a national P.I. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt, an integrated cross-departmental translational team. Locke is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy. Cancer Focus: Hodgkin Lymphoma, Leukemia, Multiple Myeloma-Plasma Cell Tumor, Non-Hodgkin Lymphomaĭr.
0 kommentar(er)
